Small molecule · developed by Novartis Pharmaceuticals
QMF149 is a drug given once daily by Breezhaler inhalation at 75/40 μg, studied in asthma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05562466 | Phase 3 | Asthma | Recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Asthma
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →